賽升藥業(300485.SZ):子公司賽而生物藥品生產許可證變更
格隆匯8月13日丨賽升藥業(300485.SZ)公佈,公司於近日收到子公司北京賽而生物藥業有限公司(“賽而生物”)的通知,其獲得了北京市藥品監督管理局頒發的《藥品生產許可證》。本次涉及變更的事項為:賽而生物《藥品生產許可證》分類碼由“AhzDhz”變更為“AhzChDhz”;增加受託生產信息,委託生產企業:長春博奧生化藥業有限公司,受託生產品種:阿替洛爾片、蛋氨酸重酒石酸膽鹼片、複方腦蛋白水解物片、琥乙紅黴素片、賴氨酸磷酸氫鈣顆粒、鹽酸二甲雙胍片、鹽酸美司坦片。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.